Skip to main content

Table 1 Demographics of subjects that were retrospectively analyzed in this work. Age is represented as mean ± standard deviation. MMSE is also represented as mean ± standard deviation. All the 109 subjects who received solanezumab were amyloid-positive and mild to moderate AD cases. YCN young cognitively normal, CN cognitively normal, MCI mild cognitive impairment, AD Alzheimer’s disease, N number of subjects, MMSE Mini-Mental State Examination, F female, M male. CD college degree or higher, HS high school or lower, C Caucasian, NC Not Caucasian (Asian, Black or African American, Other)

From: Early tau detection in flortaucipir images: validation in autopsy-confirmed data and implications for disease progression

 

YCN/Aβ-

CN/Aβ-

CN/Aβ+

MCI/Aβ-

MCI/Aβ+

AD/Aβ-

AD/Aβ+

N

16

53

5

50

47

16

240

Age

28.9 ± 4.9

67.6 ± 10.2

77.8 ± 7.0

69.1 ± 9.3

72.7 ± 9.1

72.2 ± 6.9

73.7 ± 8.3

MMSE

29.6 ± 0.5

29.5 ± 0.5

29.6 ± 0.5

28.2 ± 1.7

27.4 ± 1.8

22.9 ± 3.2

22.5 ± 2.9

Sex

7F/9M

24F/29M

2F/3M

27F/23M

21F/26M

7F/9M

135F/104M

Education

15CD/1HS

45CD/8HS

4CD/1HS

37CD/13HS

38CD/9HS

14CD/2HS

141CD/97HS

Race

11C/5NC

42C/11NC

5C/0NC

43C/7NC

45C/2NC

14C/2NC

192C/22NC